Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

被引：11
|
作者：
Rubinstein, Jeremy D. [1 ,2 ]
Nelson, Adam S. [1 ,3 ]
Krupski, Christa [1 ,3 ]
O'Brien, William [4 ,5 ]
Taylor, J. Michael [1 ,6 ]
Badgett, Tom C. [7 ]
Huang, Michael [8 ]
Davies, Stella M. [1 ,3 ]
Phillips, Christine L. [1 ,2 ]
机构：
[1] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, 3333 Burnet Ave,MLC 7015, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Coll Med, Dept Radiol, Cincinnati, OH USA
[5] Cincinnati Childrens Hosp Med Ctr, Dept Radiol & Med Imaging, Cincinnati, OH 45229 USA
[6] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA
[7] Univ Kentucky, Dept Pediat, Coll Med, Lexington, KY USA
[8] Univ Louisville, Sch Med, Pediat Canc & Blood Disorders, Louisville, KY 40292 USA
来源：
PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 04期
关键词：
CAR-T; cellular therapy; neurotoxicity; pre-B ALL; CYTOKINE RELEASE SYNDROME; NEUROTOXICITY; BIOMARKERS; CHILDREN;
D O I：
10.1002/pbc.28199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Cardiotoxicities of Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Antibodies
    Qamer, Syed Zyad
    Miraglia, Genie M.
    Granville, Matthew J.
    Finkelstein, Alexa
    Okin, Emily
    Mahmood, Syed Saad
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2024, 26 (07) : 175 - 187
  • [42] T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
    Storgard, Ryan
    Rejeski, Kai
    Perales, Miguel-Angel
    Goldman, Adam
    Shouval, Roni
    JAMA ONCOLOGY, 2024, 10 (06) : 826 - 828
  • [43] Chimeric Antigen Receptor T-Cell Therapy for T-Cell Acute Lymphocytic Leukemia
    Aldoss, Ibrahim
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2025, 23 (01) : 28 - 29
  • [44] Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
    Oh, Bernice L. Z.
    Vinanica, Natasha
    Wong, Desmond M. H.
    Campana, Dario
    HAEMATOLOGICA, 2024, 109 (06) : 1677 - 1688
  • [45] A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy
    Ruff, Michael W.
    Siegler, Elizabeth L.
    Kenderian, Saad S.
    NEUROLOGIC CLINICS, 2020, 38 (04) : 953 - 963
  • [46] Fitness criteria for Australian patients referred for chimeric antigen receptor T-cell therapy
    Tam, Constantine S.
    Ho, P. J.
    Purtill, Duncan
    Blyth, Emily
    Butler, Jason
    Dickinson, Michael
    Harrison, Simon
    INTERNAL MEDICINE JOURNAL, 2022, 52 (08) : 1454 - 1456
  • [47] Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy
    Barata, Anna
    Hoogland, Aasha I.
    Hyland, Kelly A.
    Otto, Amy K.
    Kommalapati, Anuhya
    Jayani, Reena V.
    Irizarry-Arroyo, Nathaly
    Collier, Aaron
    Rodriguez, Yvelise
    Welniak, Taylor L.
    Booth-Jones, Margaret
    Logue, Jennifer
    Small, Brent J.
    Jain, Michael D.
    Reblin, Maija
    Locke, Frederick L.
    Jim, Heather S. L.
    PSYCHO-ONCOLOGY, 2021, 30 (08) : 1294 - 1301
  • [48] Supportive care for chimeric antigen receptor T-cell patients
    Springell, Deborah
    O'Reilly, Maeve
    Roddie, Claire
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2023, 17 (03) : 231 - 239
  • [49] Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy
    Rubin, Courtney B.
    Elenitsas, Rosalie
    Taylor, Laura
    Lacey, Simon F.
    Kulikovskaya, Irina
    Gupta, Minnal
    Melenhorst, Jan J.
    Loren, Alison
    Frey, Noelle
    June, Carl H.
    Porter, David
    Rosenbach, Misha
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (05) : 1054 - 1057
  • [50] Chimeric antigen receptor T-cell therapy for T-ALL and AML
    Wei, Wenwen
    Yang, Dong
    Chen, Xi
    Liang, Dandan
    Zou, Liqun
    Zhao, Xudong
    FRONTIERS IN ONCOLOGY, 2022, 12
12345